Bath & Body Works, Inc. (NYSE:BBWI) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts maintain a “Hold” consensus on Bath & Body Works, with 15 hold, four buy, and one sell rating among 20 analysts. The average 12-month price target is $22.13, above the stock’s reported $15.96 price.
• Recent analyst actions were generally cautious: Goldman Sachs downgraded the stock to “sell” and cut its target to $19, while Baird, UBS, and Barclays also lowered targets and retained neutral or equivalent ratings.
• Bath & Body Works beat quarterly EPS expectations, reporting $0.62 versus the $0.24 consensus, although revenue fell 2.3% year over year. The company also pays a quarterly dividend of $0.20, representing a 5.0% annualized yield.

Shares of Bath & Body Works, Inc. (NYSE:BBWI - Get Free Report) have received a consensus rating of "Hold" from the twenty analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $22.13.

BBWI has been the topic of a number of recent analyst reports. Argus restated a "hold" rating on shares of Bath & Body Works in a research note on Wednesday, September 16th. The Goldman Sachs Group downgraded shares of Bath & Body Works from a "neutral" rating to a "sell" rating and lowered their price objective for the stock from $23.00 to $19.00 in a research note on Wednesday, July 8th. Robert W. Baird dropped their price objective on shares of Bath & Body Works from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Thursday, August 27th. UBS Group cut their target price on Bath & Body Works from $19.00 to $17.00 and set a "neutral" rating on the stock in a research report on Thursday, August 27th. Finally, Barclays lowered their price target on Bath & Body Works from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Thursday, August 27th.

Institutional Investors Weigh In On Bath & Body Works

Large investors have recently bought and sold shares of the company. Elevation Wealth Partners LLC raised its position in Bath & Body Works by 5,278.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 1,775 shares of the company's stock worth $41,000 after buying an additional 1,742 shares during the last quarter. Parallel Advisors LLC lifted its stake in Bath & Body Works by 35.5% during the 1st quarter. Parallel Advisors LLC now owns 2,570 shares of the company's stock valued at $48,000 after acquiring an additional 673 shares during the period. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Bath & Body Works in the 4th quarter valued at $50,000. MidFirst Bank purchased a new stake in shares of Bath & Body Works in the 4th quarter valued at $51,000. Finally, Root Financial Partners LLC increased its stake in shares of Bath & Body Works by 4,485.7% in the first quarter. Root Financial Partners LLC now owns 3,210 shares of the company's stock worth $60,000 after acquiring an additional 3,140 shares during the period. Hedge funds and other institutional investors own 95.14% of the company's stock.

Bath & Body Works Stock Performance

Shares of BBWI stock opened at $15.96 on Wednesday. Bath & Body Works has a fifty-two week low of $14.27 and a fifty-two week high of $27.40. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of 4.16, a PEG ratio of 0.81 and a beta of 1.38. The stock's 50-day simple moving average is $18.77 and its 200-day simple moving average is $19.17.

Bath & Body Works (NYSE:BBWI - Get Free Report) last announced its quarterly earnings data on Wednesday, August 26th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.24 by $0.38. The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.50 billion. Bath & Body Works had a net margin of 10.83% and a negative return on equity of 53.48%. Bath & Body Works's revenue was down 2.3% on a year-over-year basis. During the same period last year, the firm posted $0.30 EPS. Bath & Body Works has set its Q3 2026 guidance at 0.070-0.120 EPS and its FY 2026 guidance at 2.600-2.800 EPS. As a group, equities analysts forecast that Bath & Body Works will post 2.73 earnings per share for the current year.

Bath & Body Works Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Stockholders of record on Friday, August 21st were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 5.0%. The ex-dividend date was Friday, August 21st. Bath & Body Works's dividend payout ratio (DPR) is presently 20.83%.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a specialty retailer focused on personal care and home-fragrance products. Its offerings include body lotions and creams, shower gels, fragrance mists, hand soaps and sanitizers, candles, home fragrances, and related seasonal merchandise. The company markets products under the Bath & Body Works and White Barn names.

The company sells its products through a network of company-operated stores, its websites, and other direct channels. Its retail operations primarily serve customers in the United States and Canada, while international markets are reached through franchised, licensed, and other distribution arrangements.

Bath & Body Works traces its origins to 1990 and was formerly part of L Brands, Inc It became an independent publicly traded company in 2021 following the separation of L Brands' Victoria's Secret business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.